13F Holdings
中文EN

BCLI BRAINSTORM CELL THERAPEUTICS INC.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1137883 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.4%
TTM EPS YoY38.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-914.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,568.1%
Debt / equity—
Current ratio0.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-584.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$4.17M$4.65M$10.75M$13.96M$15.23M
SG&A expense$5.78M$7.04M$10.69M$10.87M$9.30M
Operating income-$9.95M-$11.69M-$21.44M-$24.82M-$24.54M
Pretax income-$10.31M-$11.62M-$17.19M-$24.28M-$24.46M
Net income-$10.31M-$11.62M-$17.19M-$24.28M-$24.46M
EBITDA-$9.75M-$11.45M-$21.17M-$24.54M-$24.28M
EPS (basic)-1.11-2.31-6.00-0.66-0.68
EPS (diluted)-1.11-2.31-6.00-0.66-0.68
Weighted avg. shares (diluted)9.27M5.02M2.87M36.51M36.18M
Balance sheet
Cash & equivalents$29,000$371,000$1.49M$772,000$18.86M
Short-term investments———$2.21M$3.24M
Current assets$307,000$385,000$1.90M$3.11M$23.28M
PP&E, net$235,000$434,000$686,000$933,000$1.19M
Total assets$1.02M$1.83M$4.21M$8.45M$29.28M
Current liabilities$11.01M$8.98M$7.80M$8.80M$6.32M
Short-term debt$967,000$300,000———
Total liabilities$11.01M$9.60M$9.07M$11.47M$9.94M
Shareholders' equity-$9.98M-$7.76M-$4.86M-$3.02M$19.34M
Shares outstanding11.03M6.14M4.03M36.69M36.40M
Cash flow statement
Operating cash flow-$6.97M-$9.09M-$20.46M-$19.32M-$26.27M
Capital expenditure——$18,000$29,000$330,000
Free cash flow——-$20.48M-$19.35M-$26.59M
Investing cash flow—$12,000$2.19M$998,000$323,000
Financing cash flow$6.88M$7.97M$18.98M$238,000$6.97M
Depreciation & amortization$199,000$240,000$265,000$285,000$260,000
Stock-based compensation$1.52M$698,000$1.49M$1.68M$1.37M

Free plan shows the latest 5 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.